Patricia Deverka

Publications and Insights

Publication: Novel devices: optimising drug delivery in multiple myeloma
Publication: A global landscape analysis of access to tumour-agnostic therapies
Publication: Achieving Accelerated Patient Access to Cancer Care in Europe
Insight: The Trump Administration’s US Drug Pricing Proposal – What will happen next?
Insight: How Widely Are QALYs Used in OECD Countries? A Snapshot of International Practices
Insight: Around the world in HTAs: Argentina – Long Road to Institutionalizing HTA
Publication: An Analysis of NICE’s Optimised Decisions from 2015 to 2024
Publication: Analysing Global Immunisation Expenditure
Publication: The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
Insight: Advancing Rare Disease Care: Challenges and Key Issues
Publication: The Importance of Diversity of Supply in Rare Diseases Markets
Insight: What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
Insight: Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
Publication: A Spotlight on Haemophilia Therapies
Publication: The Cost of Drug Shortages
Insight: Drug shortages are on the rise – but what is their impact?
Publication: Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding
Publication: A Framework for Value-aligned Pricing of Combination Therapies
Insight: NICE at 25: Technology Appraisals – Faster Access to Modern Treatment?
Publication: How Have HTA Agencies Evolved Their Methods Over Time?
Insight: Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
Publication: The Socioeconomic Burden Of Cervical Cancer in the UK: What are the benefits of achieving the WHO elimination target?
Insight: Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
Insight: Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
Publication: NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
Insight: Can a continued focus on prevention, diagnosis, and treatment see the NHS to another 75 years?
Publication: Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment
Publication: Real-World Evidence: Current Best Practice for Reimbursement Decision-Making
Bulletin: Advancing HTA through collaboration
Insight: Around The World in HTAs: Italy – What’s Next?
Publication: Delivering the Triple Win: A Value-Based Approach to Pricing
Insight: Combination Therapies: A Step Forward to the Value Attribution Problem
Publication: Navigating the Landscape of Digital Health – United Kingdom
Insight: New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)
Publication: When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies
Insight: Would Waiving COVID-19 Vaccines Patents Save Lives?
Publication: The Lower Drug Costs Now Act and Pharmaceutical Innovation
Publication: How is Quality of Life Measured for Health Technology Assessments?
Publication: Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective
Publication: Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
Publication: Realising the Broader Value of Vaccines in the UK
Publication: NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?
Publication: A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold
Publication: International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making
Publication: Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?
Publication: Unrelieved Pain in Palliative Care in England
Publication: The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
Publication: How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy
Publication: The Future of Global Health Procurement: Issues around Pricing Transparency
Publication: Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
Publication: The Impact of New Medicines in the NHS: 70 Years of Innovation
Publication: Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS
Publication: R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
Publication: Establishing a Reasonable Price for an Orphan Drug
Publication: Barriers to Uptake of Minimal Access Surgery in the United Kingdom
Publication: Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence
Publication: Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”
Publication: Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market
Publication: ‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
Publication: Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
Publication: Policy Options for Formulary Development in Middle-income Countries
Publication: Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study
Publication: Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Publication: An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’
Publication: Improving Efficiency and Resource Allocation in Future Cancer Care
Publication: Assessing Trends in SMC Advice Decisions (October 2009- September 2015)
Publication: International Comparison of Medicines Usage: Quantitative Analysis from a Swedish Perspective
Publication: Obstructive Sleep Apnoea: Health Economics Report
Publication: Exploring the Interdependencies of Research Funders in the UK
Publication: The Trajectory of Dementia in the UK – Making a Difference
Publication: The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness
Publication: Projecting Expenditure on Medicines in the NHS: Second Edition
Publication: The Influence of Cost-effectiveness and Other Factors on NICE Decisions
Publication: Exploring the link between health and wealth in decision making
Publication: Multi-Criteria Decision Analysis to Value Orphan Medicines
Publication: Projecting Expenditure on Medicines in the NHS
Publication: International Comparisons of Medicines Prices: 2011 Indices
Publication: Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
Publication: Time Trends in NICE HTA Decisions
Publication: Health and the Use of Medicines in Primary Care in Wales
Publication: Exploring the Interdependency between Public and Charitable Medical Research
Publication: Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
Publication: Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society
Publication: Shedding the Pounds: Obesity Management, NICE Guidance and Bariatric Surgery in England
Publication: Using QALYs in Cancer: Review of the Methodological Limitations
Publication: Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries
Publication: Assessment and Appraisal of Oncology Medicines: NICE’s Approach and International HTA Experience
Publication: European Medicines Pricing and Reimbursement: Now and the Future
Publication: Estimating Pharmaceutical Companies’ Value to the Nation: Case Study of the British Pharma Group